Trial reportScientific reports2025
Evaluation of the therapeutic effect of estrogen replacement therapy combined with autologous serum therapy in controlling severe dry eye disease in perimenopausal women.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Optimizing Autologous Serum Tear Therapy for Dry Eye Disease: Strategies and Innovations.Journal of clinical medicine · 2026Article
- Focus on sex hormone axis disorder: exploring the susceptibility mechanism of dry eye in perimenopausal women.Frontiers in medicine · 2026Review
- Immuno-inflammatory axis of menopausal dry eye: from hormonal fluctuations to ocular surface dysregulation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To explore the therapeutic effect of estrogen replacement therapy combined with autologous serum therapy in controlling severe dry eye disease in perimenopausal women. A total of 1249 perimenopausal female patients who visited Ziyang Hospital of West China Hospital, Sichuan University from January 2021 to December 2023 were included in this study. After screening, the patients were randomly divided into the normal group, control group, estrogen replacement therapy group (ERT), autologous serum group (AS), and estrogen replacement therapy + autologous serum group (ERT + AS). There were 20 cases in each group, totaling 100 cases. Eye surface data, total luteinizing hormone (LH), estradiol (E2), follicle stimulating hormone (FSH), and endometrial changes were collected before and after treatment in each group. After treatment, the corneal staining area and staining intensity in the ERT + AS group decreased. Compared with the average tear film rupture time of the normal group (15.16 ± 0.73) s, the Control group (5.11 ± 0.45) s decreased to the lowest level while the ERT group (8.27 ± 0.59) s, AS group (8.15 ± 0.72) s, and ERT + AS group (13.37 ± 0.85) s increased, and the ERT + AS group had the most significant increase. Besides, the Schirmer experiment results showed a consistent trend with BUT, with a statistically significant difference (P < 0.05). Meanwhile, our research had shown that after estrogen replacement therapy, FSH and LH in the ERT group and ERT + AS group were significantly reduced, while E2 was significantly increased. There was no statistically significant difference between the two groups (P > 0.05). The Elisa experiment results showed that compared with the normal group, the expression intensity of VEGF, IL-1β, PGE2, and TNF-α inflammatory factors was significantly increased in the control group. After treatment with ERT, AS, and ERT + AS, the expression of thses inflammatory factors gradually decreased, with the ERT + AS group showing the most significant downregulation (P < 0.05). The HE staining results of the endometrium indicated that after intervention measures, the thickness of the endometrium in the ERT group and ERT + AS group significantly increased, the connective tissue arrangement of the endometrium was tight, the structure of the uterine glands was dense, and there was a single layer of columnar epithelium covered with circular uterine glands. The Kupperman score demonstrated that with the prolongation of treatment time, the Kupperman scores of the ERT group and ERT + AS group gradually decreased. After 4 weeks of treatment, both groups had the lowest values, and there was no statistically significant difference between the groups (P > 0.05). Furthermore, the results of the Elisa experiment on endometrial tissue protein fluid showed that compared with the normal group, the expression intensity of IFN-α, IL-12, and TNF-α inflammatory factors was significantly increased in the control group. After treatment with ERT, AS, and ERT + AS, the expression of IFN-α, IL-12, and TNF-α inflammatory factors in the ERT group and ERT + AS group gradually decreased. There was no statistically significant difference between the two groups (P > 0.05). The Elisa experiment results showed that compared with the normal group, the expression intensity of LZM, LF, ALB and sIgA in the control group was significantly decreased, and the difference between the two groups was statistically significant (P < 0.05). After treatment with ERT, AS, and ERT + AS, the expression of inflammatory factors LZM, LF, ALB and sIgA gradually increased, with the ERT + AS group showing the most significant upregulation, and the difference was statistically significant (P < 0.05). The combination of estrogen replacement therapy and autologous serum therapy can effectively ameliorate the symptoms of severe dry eye disease in perimenopausal women and improve their quality of life, which is worthy of further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.